Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Abstract

A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.

Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)

“…Thus, there is a need to better model these regional differences not only by understanding their impact on the solubility of the drug but also on its permeability. Although the dynamic model of the total bile salt regional profile is provided in a Simcyp ® v20 simulator with inter- and intra-subject variability [ 13 , 29 ], the lack of regional time variant composition of mixed micelles and the corresponding pH- and non-pH dependent drug–micelles interactions limits the ability to mechanistically understand these phenomena. For instance, it was challenging to develop a meal-specific PBBM model to understand the lower Cmax and AUC observed with a high-fat meal compared to a moderate-fat meal.…”

How to engineer aerosol particle properties and biopharmaceutical performance of propellant inhalers

“…As beclomethasone dipropionate has low aqueous solubility, lung exposure and absorption from the lungs may be anticipated to be dissolution rate dependent. Thus, under general frameworks for ‘clinically-relevant dissolution’ ( McAllister et al, 2022 ) and specific proposals for an inhaled bioclassification system ( Hastedt et al, 2022 , Bäckman et al, 2022 ) dissolution may be considered a key quality attribute linked to clinical performance. Following evaporation of propellant and then ethanol, particles consist principally of the BDP and glycerol or isopropyl myristate, with a degree of water content as discussed above.…”

Virtual Bioequivalence in Pharmaceuticals: Current Status and Future Prospects

“…VBE contributes to establishing dissolution specifications with clinical relevance, considering the impact of dissolution on drug performance and therapeutic outcomes. Additionally, computational models can predict the effect of food on drug absorption, aiding in understanding the potential variations in bioavailability under different dietary conditions [31][32][33].…”